{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"MTD was defined as the highest dose level at which no more than 1/6 participants experienced a dose limiting toxicity (DLTs), with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. DLT was graded according to common terminology criteria for adverse events (CTCAE) version 4.03.","groups":[{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 8 or 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG000","title":"Phase 1: Lenvatinib + Everolimus (All Participants)"}],"paramType":"NUMBER","populationDescription":"SAS included all participants who received at least one dose of study drug (Lenvatinib or Everolimus).","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Each cycle was of 28 days)","title":"Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus","type":"PRIMARY","unitOfMeasure":"milligram per square meter (mg/m^2)"}